Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Supply, Demand and Key Producers, 2023-2029
Page: 112
Published Date: 06 Sep 2023
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
The global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat.
This report studies the global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Oculopharyngeal Muscular Dystrophy (OPMD) Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs total production and demand, 2018-2029, (K Units)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs total production value, 2018-2029, (USD Million)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs domestic production, consumption, key domestic manufacturers and share
Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).
This reports profiles key players in the global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market, Segmentation by Type
Tablets
Capsules
Injectable
Other
Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market, Segmentation by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Companies Profiled:
Benitec Biopharma Inc.
Bioblast Pharma
BioMarin
PTC Therapeutics
NS Pharma
Nobelpharma Co., Ltd
Santhera Pharmaceuticals
Pfizer Inc.
Marathon Pharmaceuticals
Fibrogen
Bristol-Myers Squibb
Sarepta Therapeutics
GSK
Key Questions Answered
1. How big is the global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market?
2. What is the demand of the global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market?
3. What is the year over year growth of the global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market?
4. What is the production and production value of the global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market?
5. Who are the key producers in the global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market?
Table of Contents
1 Supply Summary
1.1 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Introduction
1.2 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Supply & Forecast
1.2.1 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value (2018 & 2022 & 2029)
1.2.2 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2029)
1.2.3 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Pricing Trends (2018-2029)
1.3 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production by Region (Based on Production Site)
1.3.1 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Region (2018-2029)
1.3.2 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production by Region (2018-2029)
1.3.3 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Region (2018-2029)
1.3.4 North America Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2029)
1.3.5 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2029)
1.3.6 China Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2029)
1.3.7 Japan Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Major Market Trends
2.1 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Demand (2018-2029)
2.2 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption by Region
2.2.1 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption by Region (2018-2023)
2.2.2 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption Forecast by Region (2024-2029)
2.3 United States Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029)
2.4 China Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029)
2.5 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029)
2.6 Japan Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029)
2.7 South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029)
2.8 ASEAN Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029)
2.9 India Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029)
3.1 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Manufacturer (2018-2023)
3.2 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production by Manufacturer (2018-2023)
3.3 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Manufacturer (2018-2023)
3.4 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Oculopharyngeal Muscular Dystrophy (OPMD) Drugs in 2022
3.5.3 Global Concentration Ratios (CR8) for Oculopharyngeal Muscular Dystrophy (OPMD) Drugs in 2022
3.6 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market: Overall Company Footprint Analysis
3.6.1 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market: Region Footprint
3.6.2 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market: Company Product Type Footprint
3.6.3 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4.1 United States VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Comparison
4.1.1 United States VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Comparison
4.2.1 United States VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption Comparison
4.3.1 United States VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value (2018-2023)
4.4.3 United States Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2023)
4.5 China Based Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Manufacturers and Market Share
4.5.1 China Based Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value (2018-2023)
4.5.3 China Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2023)
4.6 Rest of World Based Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2023)
5.1 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Tablets
5.2.2 Capsules
5.2.3 Injectable
5.2.4 Other
5.3 Market Segment by Type
5.3.1 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production by Type (2018-2029)
5.3.2 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Type (2018-2029)
5.3.3 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Type (2018-2029)
6.1 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Segment by Application
6.3.1 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production by Application (2018-2029)
6.3.2 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Application (2018-2029)
6.3.3 World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Application (2018-2029)
7.1 Benitec Biopharma Inc.
7.1.1 Benitec Biopharma Inc. Details
7.1.2 Benitec Biopharma Inc. Major Business
7.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.1.4 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Benitec Biopharma Inc. Recent Developments/Updates
7.1.6 Benitec Biopharma Inc. Competitive Strengths & Weaknesses
7.2 Bioblast Pharma
7.2.1 Bioblast Pharma Details
7.2.2 Bioblast Pharma Major Business
7.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.2.4 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Bioblast Pharma Recent Developments/Updates
7.2.6 Bioblast Pharma Competitive Strengths & Weaknesses
7.3 BioMarin
7.3.1 BioMarin Details
7.3.2 BioMarin Major Business
7.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.3.4 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 BioMarin Recent Developments/Updates
7.3.6 BioMarin Competitive Strengths & Weaknesses
7.4 PTC Therapeutics
7.4.1 PTC Therapeutics Details
7.4.2 PTC Therapeutics Major Business
7.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.4.4 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 PTC Therapeutics Recent Developments/Updates
7.4.6 PTC Therapeutics Competitive Strengths & Weaknesses
7.5 NS Pharma
7.5.1 NS Pharma Details
7.5.2 NS Pharma Major Business
7.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.5.4 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 NS Pharma Recent Developments/Updates
7.5.6 NS Pharma Competitive Strengths & Weaknesses
7.6 Nobelpharma Co., Ltd
7.6.1 Nobelpharma Co., Ltd Details
7.6.2 Nobelpharma Co., Ltd Major Business
7.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.6.4 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Nobelpharma Co., Ltd Recent Developments/Updates
7.6.6 Nobelpharma Co., Ltd Competitive Strengths & Weaknesses
7.7 Santhera Pharmaceuticals
7.7.1 Santhera Pharmaceuticals Details
7.7.2 Santhera Pharmaceuticals Major Business
7.7.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.7.4 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Santhera Pharmaceuticals Recent Developments/Updates
7.7.6 Santhera Pharmaceuticals Competitive Strengths & Weaknesses
7.8 Pfizer Inc.
7.8.1 Pfizer Inc. Details
7.8.2 Pfizer Inc. Major Business
7.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.8.4 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Pfizer Inc. Recent Developments/Updates
7.8.6 Pfizer Inc. Competitive Strengths & Weaknesses
7.9 Marathon Pharmaceuticals
7.9.1 Marathon Pharmaceuticals Details
7.9.2 Marathon Pharmaceuticals Major Business
7.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.9.4 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Marathon Pharmaceuticals Recent Developments/Updates
7.9.6 Marathon Pharmaceuticals Competitive Strengths & Weaknesses
7.10 Fibrogen
7.10.1 Fibrogen Details
7.10.2 Fibrogen Major Business
7.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.10.4 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Fibrogen Recent Developments/Updates
7.10.6 Fibrogen Competitive Strengths & Weaknesses
7.11 Bristol-Myers Squibb
7.11.1 Bristol-Myers Squibb Details
7.11.2 Bristol-Myers Squibb Major Business
7.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.11.4 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Bristol-Myers Squibb Recent Developments/Updates
7.11.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
7.12 Sarepta Therapeutics
7.12.1 Sarepta Therapeutics Details
7.12.2 Sarepta Therapeutics Major Business
7.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.12.4 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Sarepta Therapeutics Recent Developments/Updates
7.12.6 Sarepta Therapeutics Competitive Strengths & Weaknesses
7.13 GSK
7.13.1 GSK Details
7.13.2 GSK Major Business
7.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
7.13.4 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.13.5 GSK Recent Developments/Updates
7.13.6 GSK Competitive Strengths & Weaknesses
8.1 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Industry Chain
8.2 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Upstream Analysis
8.2.1 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Core Raw Materials
8.2.2 Main Manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Mode
8.6 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Procurement Model
8.7 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Industry Sales Model and Sales Channels
8.7.1 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales Model
8.7.2 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Typical Customers
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Region (2018-2023) & (USD Million)
Table 3. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Region (2024-2029) & (USD Million)
Table 4. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Market Share by Region (2018-2023)
Table 5. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Market Share by Region (2024-2029)
Table 6. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production by Region (2018-2023) & (K Units)
Table 7. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production by Region (2024-2029) & (K Units)
Table 8. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share by Region (2018-2023)
Table 9. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share by Region (2024-2029)
Table 10. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Major Market Trends
Table 13. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption by Region (2018-2023) & (K Units)
Table 15. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Producers in 2022
Table 18. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Producers in 2022
Table 20. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Company Evaluation Quadrant
Table 22. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Site of Key Manufacturer
Table 24. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market: Company Product Type Footprint
Table 25. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market: Company Product Application Footprint
Table 26. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Competitive Factors
Table 27. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs New Entrant and Capacity Expansion Plans
Table 28. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share (2018-2023)
Table 37. China Based Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share (2018-2023)
Table 42. Rest of World Based Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share (2018-2023)
Table 47. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production by Type (2018-2023) & (K Units)
Table 49. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production by Type (2024-2029) & (K Units)
Table 50. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Type (2018-2023) & (USD Million)
Table 51. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Type (2024-2029) & (USD Million)
Table 52. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production by Application (2018-2023) & (K Units)
Table 56. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production by Application (2024-2029) & (K Units)
Table 57. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Application (2018-2023) & (USD Million)
Table 58. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Application (2024-2029) & (USD Million)
Table 59. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Benitec Biopharma Inc. Basic Information, Manufacturing Base and Competitors
Table 62. Benitec Biopharma Inc. Major Business
Table 63. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 64. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Benitec Biopharma Inc. Recent Developments/Updates
Table 66. Benitec Biopharma Inc. Competitive Strengths & Weaknesses
Table 67. Bioblast Pharma Basic Information, Manufacturing Base and Competitors
Table 68. Bioblast Pharma Major Business
Table 69. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 70. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Bioblast Pharma Recent Developments/Updates
Table 72. Bioblast Pharma Competitive Strengths & Weaknesses
Table 73. BioMarin Basic Information, Manufacturing Base and Competitors
Table 74. BioMarin Major Business
Table 75. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 76. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. BioMarin Recent Developments/Updates
Table 78. BioMarin Competitive Strengths & Weaknesses
Table 79. PTC Therapeutics Basic Information, Manufacturing Base and Competitors
Table 80. PTC Therapeutics Major Business
Table 81. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 82. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. PTC Therapeutics Recent Developments/Updates
Table 84. PTC Therapeutics Competitive Strengths & Weaknesses
Table 85. NS Pharma Basic Information, Manufacturing Base and Competitors
Table 86. NS Pharma Major Business
Table 87. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 88. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. NS Pharma Recent Developments/Updates
Table 90. NS Pharma Competitive Strengths & Weaknesses
Table 91. Nobelpharma Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 92. Nobelpharma Co., Ltd Major Business
Table 93. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 94. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Nobelpharma Co., Ltd Recent Developments/Updates
Table 96. Nobelpharma Co., Ltd Competitive Strengths & Weaknesses
Table 97. Santhera Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 98. Santhera Pharmaceuticals Major Business
Table 99. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 100. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Santhera Pharmaceuticals Recent Developments/Updates
Table 102. Santhera Pharmaceuticals Competitive Strengths & Weaknesses
Table 103. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 104. Pfizer Inc. Major Business
Table 105. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 106. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Pfizer Inc. Recent Developments/Updates
Table 108. Pfizer Inc. Competitive Strengths & Weaknesses
Table 109. Marathon Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 110. Marathon Pharmaceuticals Major Business
Table 111. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 112. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. Marathon Pharmaceuticals Recent Developments/Updates
Table 114. Marathon Pharmaceuticals Competitive Strengths & Weaknesses
Table 115. Fibrogen Basic Information, Manufacturing Base and Competitors
Table 116. Fibrogen Major Business
Table 117. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 118. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Fibrogen Recent Developments/Updates
Table 120. Fibrogen Competitive Strengths & Weaknesses
Table 121. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 122. Bristol-Myers Squibb Major Business
Table 123. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 124. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Bristol-Myers Squibb Recent Developments/Updates
Table 126. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 127. Sarepta Therapeutics Basic Information, Manufacturing Base and Competitors
Table 128. Sarepta Therapeutics Major Business
Table 129. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 130. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 131. Sarepta Therapeutics Recent Developments/Updates
Table 132. GSK Basic Information, Manufacturing Base and Competitors
Table 133. GSK Major Business
Table 134. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product and Services
Table 135. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 136. Global Key Players of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Upstream (Raw Materials)
Table 137. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Typical Customers
Table 138. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Typical Distributors
List of Figure
Figure 1. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Picture
Figure 2. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2029) & (K Units)
Figure 5. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price (2018-2029) & (US$/Unit)
Figure 6. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Market Share by Region (2018-2029)
Figure 7. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share by Region (2018-2029)
Figure 8. North America Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2029) & (K Units)
Figure 9. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2029) & (K Units)
Figure 10. China Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2029) & (K Units)
Figure 11. Japan Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production (2018-2029) & (K Units)
Figure 12. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029) & (K Units)
Figure 15. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption Market Share by Region (2018-2029)
Figure 16. United States Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029) & (K Units)
Figure 17. China Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029) & (K Units)
Figure 18. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029) & (K Units)
Figure 19. Japan Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029) & (K Units)
Figure 20. South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029) & (K Units)
Figure 22. India Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Markets in 2022
Figure 26. United States VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share 2022
Figure 30. China Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share 2022
Figure 32. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Market Share by Type in 2022
Figure 34. Tablets
Figure 35. Capsules
Figure 36. Injectable
Figure 37. Other
Figure 38. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share by Type (2018-2029)
Figure 39. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Market Share by Type (2018-2029)
Figure 40. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 41. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 42. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Market Share by Application in 2022
Figure 43. Hospital Pharmacies
Figure 44. Retail Pharmacies
Figure 45. Online Pharmacies
Figure 46. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Market Share by Application (2018-2029)
Figure 47. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Value Market Share by Application (2018-2029)
Figure 48. World Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 49. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Industry Chain
Figure 50. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Procurement Model
Figure 51. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales Model
Figure 52. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales Channels, Direct Sales, and Distribution
Figure 53. Methodology
Figure 54. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Benitec Biopharma Inc. Bioblast Pharma BioMarin PTC Therapeutics NS Pharma Nobelpharma Co., Ltd Santhera Pharmaceuticals Pfizer Inc. Marathon Pharmaceuticals Fibrogen Bristol-Myers Squibb Sarepta Therapeutics GSK
Related Reports
06 Sep 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
